Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, ventilation, or.. 96% Improvement Relative Risk c19early.org/e Kevorkian et al. Aspirin for COVID-19 LATE TREATMENT Is late treatment with aspirin+combined treatments beneficial for COVID-19? Retrospective 68 patients in France (January - November 2020) Lower progression with aspirin+combined treatments (p=0.0005) Kevorkian et al., J. Infection, doi:10.1016/j.jinf.2021.02.008 Favors aspirin Favors control
Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study
Kevorkian et al., Journal of Infection, doi:10.1016/j.jinf.2021.02.008
Kevorkian et al., Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized.., Journal of Infection, doi:10.1016/j.jinf.2021.02.008
Jun 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Observational study in France with 28 hospitalized patients treated with prednisone/furosemide/colchicine/salicylate/direct anti-Xa inhibitor, and 40 control patients, showing lower combined mortality, ventilation, or high-flow oxygen therapy with treatment. This study is excluded in meta analysis: combined treatments may contribute more to the effect seen.
risk of mortality, ventilation, or high-flow oxygen therapy, 95.7% lower, OR 0.04, p < 0.001, treatment 28, control 40, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kevorkian et al., 30 Jun 2021, retrospective, France, peer-reviewed, 11 authors, study period 9 January, 2020 - 30 November, 2020, this trial uses multiple treatments in the treatment arm (combined with prednisone, furosemide, salicylate, direct anti-Xa inhibitor) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Journal of Infection 82 (2021) 276–316 Contents lists available at ScienceDirect Journal of Infection journal homepage: www.elsevier.com/locate/jinf Letters to the Editor Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate Dear Editor,
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit